Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period

Tomasz Pertyński; Grzegorz Stachowiak

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2008
vol. 7

Send email

Copy url:

abstract:

Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period

Tomasz Pertyński

,

Grzegorz Stachowiak

Przegląd Menopauzalny 2008; 1: 1–8

Online publish date: 2008/03/03

View full text Get citation

Estradiol (E2) and dydrogesterone have been present in oral hormone therapy (HT) of the menopausal period for some years. E2/dydrogesterone preparations attainable in Poland at present show high therapeutic efficacy both as continuous (including low-dose) and sequential HT. This oestrogen-progestogen combination is characterized by an exceptionally advantageous pharmacological profile (with a favourable influence on lipid profile, carbohydrate metabolism, blood pressure or skin) and high therapeutic safety (an impact on endometrium, uterine bleeding profile and breast tissues). This type of HT should be one of the basic therapeutic options for menopausal women in need of hormonal treatment.

keywords:

Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period

Tomasz Pertyński , Grzegorz Stachowiak

estradiol, dydrogesterone, oral hormone therapy, menopause

Tomasz Pertyński

,

Grzegorz Stachowiak